This page shows the latest Striverdi news and features for those working in and with pharma, biotech and healthcare.
Spiolto - which combines the active ingredients in Boehringer's long-acting muscarinic antagonist Spiriva (tiotropium) and long-acting beta agonist Striverdi (olodaterol) - was recently approved for marketing in the EU and
s recently launched Striverdi product.
Stiolto contains the active ingredient in Spiriva - long-acting muscarinic antagonist (LAMA) tiotropium - with long-acting beta agonist (LABA) olodaterol that is sold as a monotherapy under the Striverdi brand name.
FDA approves Boehringer COPD spray Striverdi Respimat. Licence from US regulator will also allow it to treat chronic bronchitis or emphysema. ... Boehringer Ingelheim's once-daily chronic obstructive pulmonary disease (COPD) spray Striverdi Respimat
The drug combines Boehringer's huge selling Spiriva (tiotropium) with another of its respiratory treatments Striverdi (olodaterol). ... Striverdi is yet to hit the same lofty heights as Spiriva, having only received approval earlier this year.
up that combines tiotropium with the company's long-acting beta agonist Striverdi (olodaterol).
More from news
Approximately 2 fully matching, plus 5 partially matching documents found.
Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...